Table 2 Transplant outcomes
Parameter | Low-risk arm (group C, N=105) | High-risk arm | |
|---|---|---|---|
NAC prophylaxis cohort (group A, N=80) | High-risk control cohort (group B, N=40) | ||
Median days of neutrophil engraftment (range) | 13 (11–42) | 12 (11–14) | 12 (11–14) |
Median days of platelet engraftment (range) | 13 (9–168) | 13 (9–217) | 13 (10–219) |
Acute GVHD at day 100, %(95% CI) | 17.4(10.0–29.8) | 26.2(16.6–35.8) | 25.3(11.3–39.3) |
CMV reactivation at day 100, %(95% CI) | 84.8(78.0–91.6) | 87.5(80.1–94.9) | 85.0(73.2–95.8) |
EBV reactivation at day 100, % (95% CI) | 15.4( 8.0–22.8) | 11.3(3.9–18.7) | 12.7(2.1–23.3) |
1-year incidence of relapse, %(95% CI) | 6.7(1.0–12.3) | 5.2(0–11.2) | 6.5(0–15.5) |
1-year incidence of NRM, %(95% CI) | 3.2(0–6.6) | 9.1(1.1 17.1) | 6.4(0–15.4) |
1-year probability of LFS, %(95% CI) | 90.1(83.3–96.9) | 85.8(77.5 95.0) | 87.0(74.6–99.4) |
1-year probability of OS, %(95% CI) | 95.7(91.5–100) | 88.3(79.1–97.5) | 89.8(78.4–100) |